Saturday 17 October 2026
Export INBS’s income statement to Excel — free account
Intelligent Bio Solutions Inc.
INBS Healthcare Medical Devices
Intelligent Bio Solutions Inc.’s revenue for fiscal 2026 (year ended June 2026) was $4.2 million, up 38.1% from fiscal 2025. In the quarter to June 2026, revenue grew 51.1%, EPS grew 78.1% and free cash flow fell 31.6%, each against the same quarter a year earlier.
1.50
0.06
+4.17%
Follow INBS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.80 | 1.39 | 2.57 | 2.65 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.06) | (1.23) | (5.78) | (3.06) | |
P/B ratio |
0.64 | 0.61 | 0.83 | 2.54 | |
Price to Tangible BV |
1.36 | 0.93 | 1.19 | 0.00 | |
EV/Sales |
0.43 | 0.24 | 3.05 | 2.88 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.15) | (0.08) | (1.15) | (0.94) | |
EV/FCF |
(0.15) | (0.08) | (1.11) | (0.90) | |
Quick Ratio |
1.15 | 1.80 | 2.17 | 0.65 | |
Current Ratio |
1.44 | 2.11 | 2.37 | 0.89 | |
Net Debt/EBITDA |
1.12 | 2.44 | 0.32 | 0.61 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.42 | 0.32 | 0.27 | 0.30 | |
Operating CF/Net income |
0.81 | 1.51 | 0.59 | 0.95 | |
Capex/Depreciation |
0.00 | 0.04 | (0.30) | 0.00 | |
Interest Coverage |
72.11 | (739.90) | (46.90) | (769.13) | |
Research and Development Expense of Revenue |
136.89% | 84.28% | 53.85% | 43.73% | |
Selling, General and Administrative Expense of Revenue |
283.92% | 231.77% | 241.05% | 239.23% | |
Intangible Assets out of Total Assets |
0.23 | 0.20 | 0.19 | 0.35 | |
Share Based Compensation of Revenue |
9.08% | 2.28% | 6.35% | 1.08% | |
Graham Net Nets |
0.13 | 0.68 | 0.60 | (0.24) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(392.17%) | (364.78%) | (155.51%) | (166.67%) | |
Free Cash Flow Yield |
(360.81%) | (210.86%) | (107.16%) | (120.85%) | |
Revenue per Share |
0.73 | 0.67 | 1.02 | 1.30 | |
Operating CF per Share |
(2.16) | (2.72) | (1.65) | (3.33) | |
Capex per Share |
0.00 | 0.01 | (0.10) | 0.00 | |
Free Cash Flow per Share |
(2.16) | (2.71) | (1.75) | (3.33) | |
Cash per Share |
2.71 | 4.30 | 0.78 | 1.94 | |
Shareholders Equity per Share |
3.59 | 5.49 | 11.45 | 4.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.59 | 5.49 | 11.45 | 4.01 | |
Free Cash Flow |
(3.18) | (4.32) | (1.67) | (2.85) | |
Working Capital |
2.17 | 5.14 | 7.05 | (0.58) | |
Capital Expenditures |
0.00 | 0.01 | (0.10) | — | |
Net Current Asset Value |
0.45 | 3.64 | 5.41 | (2.13) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | (0.01) | 0.10 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.49 | 1.24 | 5.50 | 1.43 | |
Average Payables |
4.33 | 2.48 | 2.67 | 2.91 | |
Average Inventory |
0.53 | 0.64 | 0.65 | 0.68 | |
Average Assets |
10.10 | 12.22 | 13.17 | 10.88 | |
Average Common Equity |
4.05 | 6.85 | 7.55 | 4.69 |
Columns are period end dates